The Claim
The Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio maintains high diagnostic accuracy when amyloid status is determined by cerebrospinal fluid biomarkers or by amyloid PET imaging.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
The blood test that measures the ratio of pTau217 to β-Amyloid 1-42 accurately identifies amyloid buildup in the brain whether the diagnosis is confirmed by spinal fluid analysis or brain imaging.
See the scientific wording
The Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio maintains high diagnostic accuracy regardless of whether amyloid status is determined by cerebrospinal fluid biomarkers or amyloid PET imaging, indicating that the test is robust to the choice of reference standard.
The ratio of pTau217 to β-Amyloid 1-42 in blood directly mirrors the amount of abnormal tau and amyloid proteins in the brain, so it accurately shows whether Alzheimer’s changes are present, no matter how those changes are measured in the brain.
What the research says
1 studyThis blood test works just as well whether doctors use spinal fluid tests or brain scans to confirm Alzheimer’s changes—it’s accurate either way.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.